The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial
Key facts
- Who runs it
- Shanghai Eye Disease Prevention and Treatment Center
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 219 people enrolled
- Started
- 4 Jul 2021
- Ended
- 1 Sept 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atropine
- Record updated
- 12 March 2026
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- At least one eye with cycloplegic optometric spherical equivalent of -5.00 to -10.00D and best corrected distant visual acuity of at least 0.5 and near visual acuity of at least 1.0, Titmus Stereo acuity ≤ 80 seconds, Vision with external occultation of ≤ 10 prismatic diopters , vision with internal occultation of ≤ 6-8 prismatic diopters, and astigmatism equal to or less than -2.50D
- Myopia progression greater than 0.5D in the past year
- Possess normal cognitive and verbal communication abilities to actively cooperate with the prescribed treatment
- Written informed consent from the guardian and the child
Who cannot take part
- Previous treatment with anticholinergics including atropine within the previous 1 year, or use of OK lenses, multifocal soft lenses within 3 months
- Diseases of the study eye: keratitis, cone cornea, congenital cataract, glaucoma, fundus diseases; combined with inflammation of the anterior or posterior segment of the eye, such as acute conjunctivitis, iridocyclitis
- Systemic diseases affecting the use of drugs: albinism, epilepsy, severe psychoneurological disorders, congenital heart disease, cardiac arrhythmias
- Atropine allergy
- Other conditions judged by the investigator to be unsuitable for participation in the trial
- Very low birth weight less than 1500 g
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Objective: to evaluate the efficacy of different concentrations of atropine eye drops in controlling the progression (diopter, axial length) of high myopia in young children, and to compare the compliance, adverse reaction and regression rate of different concentrations of atropine eye drops in myopia control.
Read full original descriptionShow less
Intervention: Group 1 (0.01% atropine group), Group 2 (0.04% atropine group), Group 3 (0.1% atropine group). During the 2-year intervention period after entering the group, each concentration of atropine eye drops were given every night at a fixed time before going to bed, one drop each time, implemented by parents (supervision), and the wechat small program was completed.
The 3 groups in the trial
- Group 1Existing treatment, for comparison
0.01% atropine
Treatment: Atropine
- Group 2Treatment being tested
0.04% atropine
Treatment: Atropine
- Group 3Treatment being tested
0.1% atropine
Treatment: Atropine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Shanghai Eye Disease Prevention and Treatment Center
- Publications
- Record updated
- 12 March 2026